COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure — COPILOT-HF  

Heart Failure Clinical Trial

Official title: COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure

Status Recruiting

Clinical Trial Summary

This is a randomized, open-label, initiative within the Mass General Brigham healthcare system testing two remote care strategies for optimizing the prescription of guideline-directed medical therapies in patients with heart failure, regardless of left ventricular ejection fraction (LVEF).

Clinical Trial Description

The primary objectives are:

1. Determine if a remote, or virtual, clinic that implements a standardized, stepped-approach to guideline-directed medication optimization in patients with heart failure (across the spectrum of ejection fraction), will achieve a higher rate of guideline-directed medical therapy (GDMT) than a strategy of patient and provider education followed by remote heart failure clinic management.

2. In eligible patients with LVEF<50%, determine if the sequencing of GDMT initiation (traditional vs. sodium-glucose co-transporter-2 inhibitors-first) leads to improved GDMT intensification ;

Related Conditions & MeSH terms

• Heart Failure

• NCT number: NCT05734690
• Study type: Interventional
• Source: Brigham and Women's Hospital
• Contact: Daniel Gabovitch, MGB
• Phone: 6177633692
• Email: dgabovitch@bwh.harvard.edu
• Status: Recruiting
• Phase: Phase 4
• Start date: May 5, 2023
• Completion date: June 2025